Final Results

McBride PLC 24 October 2000 McBride plc Preliminary Announcement for the Year ended 30 June 2000 McBride plc, the largest manufacturer of private label household, personal care and OTC pharmaceutical products in Europe, announces its preliminary results for the year ended 30 June 2000. Highlights * A 7.0% increase in sales in local currency, excluding the share of the joint venture, with UK sales up 10.2% and Continental Europe up 3.8% * In Continental Europe core sales of private label and minor brand in local currency up 6.4% * Operating profit of £32.5 million, before goodwill amortisation, operating exceptional items and share of the joint venture compared with £34.9 million * Profit before taxation, goodwill amortisation, operating exceptional items and share of the joint venture was £26.1 million compared with £30.0million * Basic earnings per share of 8.7 pence compared with 6.5 pence * Interest cover of 5.1 times compared with 7.1 times * Total dividend of 4.6 pence compared with 7.5 pence Strategic actions * Acquisition of Wrafton Laboratories has taken McBride into the growth market for OTC pharmaceuticals * Aerosol Products Limited, a joint venture with Nichol Beauty Products Limited created the UK's largest manufacturer of retailer brand aerosols * The Eastern European business based in Poland continued to perform strongly throughout the year Outlook The difficult trading conditions experienced in the main UK and Continental European businesses during the second half, which resulted from the combination of competitive pricing and raw material and packaging price inflation, have continued through the first quarter of the current financial year. The dilution of the Company's Continental European performance caused by the weak euro has also continued. The performance of Wrafton in the OTC pharmaceutical market, and of Intersilesia in Eastern Europe remain strong. Measures have been identified to increase sales, mitigate inflationary input costs and reduce all other costs, and these are being implemented. It is difficult, however, to estimate when the impact of these measures will be realised and to forecast the outcome for the year. It was announced on 2 June 2000 that the Board was reviewing the Company's strategic options in order to maximise shareholder value. On 26 September 2000 the Company announced that it had received a number of preliminary enquiries from interested parties concerning a possible offer for the Company. Discussions are at an early stage and are continuing. Whilst there can be no certainty at this stage that any transaction will result, an announcement will be made as further developments occur. For further information please contact: Financial Dynamics 020 7831 3113 Andrew Dowler Chairman's Statement In my statement last year I started by saying that it had been a very challenging period for McBride. The tough trading conditions of that year continued throughout 1999/2000 but much has been achieved in terms of strategic progress. The acquisition of Wrafton Laboratories has taken McBride into the important and growing market for OTC pharmaceuticals and represents McBride's first strategic move outside household and personal care. In November 1999 we also announced the creation of Aerosol Products Ltd as a joint venture with Nichol Beauty Products. This private label aerosol business is now the largest of its kind in Europe. Our principal markets in the UK and Continental Europe continued to grow as major retailers demonstrated their continuing faith in the benefits of private label. On the Continent in particular retailers are becoming more determined to exploit the private label opportunity. McBride developed and launched several new products for customers experimenting with retailer brands for the first time. In McBride's most important sector, household products, sales of branded products gave up further market share to private label despite unprecedented levels of product innovation, advertising expenditure and price promotions by the major brand manufacturers. Although the year has been a good one in terms of strategic progress the financial results have been disappointing. After a strong performance in the first half of the year, the second half proved more difficult. In the UK the competitive conditions experienced in the previous two years persisted. In Continental Europe sales and trading profit for the year in local currency showed encouraging growth, but when translated into sterling the results were adversely affected by the weakness of the euro. Profit before taxation, goodwill amortisation, operating exceptional items, and the effect of the Aerosol Products joint venture, was £26.1 million compared with £30.0 million in the previous year. Earnings per share, again before goodwill amortisation, operating exceptional items and the joint venture, were 10.8 pence compared with 12.7 pence. The performance of Aerosol Products Ltd was a significant disappointment in the year. McBride's share of the operating loss for the period to 30 June 2000 was £2.4 million. However, the strategic rationale for creating APL, namely combining two large private label/contract manufacturers into a single leading supplier remains valid. The penetration of private label aerosols is low and provides an opportunity for growth. The Board of APL believes the business is now on track to recover in 2000/01. Despite the difficult trading conditions McBride has achieved sound progress towards its strategic goals and this reflects the hard work, dedication and commitment of our employees. On behalf of the Board and shareholders I would like to give them my heartfelt thanks. Dividend Bearing in mind the uncertainty of the discussions with interested parties, which were announced on 26 September 2000, the Board has determined to rebase the level of dividend, having regard to an appropriate level of dividend cover. The Board is therefore proposing a final dividend for the year ended 30 June 2000 of 2.0 pence, giving a total dividend of 4.6 pence for the year. Allen Sheppard 23 October 2000 Chief Executive's Statement McBride has been developed into a truly European business with operations in most of Europe's major markets, and is actively developing new strengths in Eastern Europe. Nevertheless, widely differing operating conditions continued to be experienced from area to area. In the UK volumes were good but prices came under severe pressure in very tough trading conditions. In Continental Europe in general and in France in particular demand for McBride's products gained momentum but margins came under pressure in the second half. In Poland trading was very strong. Whilst total sterling reported sales of £496.8 million were unchanged from the previous year, the weakness of the euro reduced sales on translation into sterling by £18.0 million. After allowing for this currency effect and excluding the joint venture, sales growth of 7% was achieved. The reported operating profit before goodwill amortisation, operating exceptional items and the impact of the joint venture, was £32.5 million compared with £34.9 million last year. The adverse currency effect reduced profit on translation by £1.1 million. United Kingdom The challenging market conditions for consumer goods and strong competitor activity from branded products, which have been noted in previous reports, persisted throughout the year. Sales of household and personal care products were £255.9 million compared with £265.1 million in the previous year. However, after allowing for the effect of the transfer of the Hull aerosol sales to the joint venture, UK sales grew by an underlying 2.2%. In addition, Wrafton's OTC pharmaceutical sales contributed £18.5 million from September 1999. Therefore overall UK sales growth, including the acquisition of Wrafton Laboratories, was 10.2%. As part of McBride's continuing programme of product innovation further new variants of textile washing tablets were launched during the year. The tablets, which can be placed in either the drawer or the drum of the washing machine, have faster dissolving properties. By the end of the financial year the tablet share of the UK textile wash market had risen to 27%, with private label's share of tablets reaching 18%. The UK market for personal care products has been intensely competitive for some time and remained so throughout the year. The total market was largely unchanged with price reductions and promotional activity continuing to be key features. The private label segment declined under pressure from the marketing activity of the major brand manufacturers. However McBride successfully launched its first own label striped toothpaste with a major retail customer. In addition a premium men's range was also launched and a number of products were re-launched during the year. The expansion of McBride's textile washing powder capacity at Barrow was completed and officially opened on 16 June 2000. This state-of-the-art facility is capable of providing a wide range of high quality powders and tablets. Investment also continued on the implementation phase of the SAP R/3 integrated management information system. Continental Europe The sterling reported sales in Continental Europe of £222.4 million for 1999/2000 showed a decline of £9.3 million from the previous year. However, in constant currency terms total sales grew 3.8% while sales of the core private label and minor brand business grew 6.4%. This underlying increase reflected a further improvement in France, which was helped by the integration of the acquisitions completed in 1998. The value of the private label household products market in France grew encouragingly in the year to December 1999, reaching 9.6% value share and 13% volume share. McBride's sales in Spain recorded significant growth as a result of increased volumes with two major Spanish supermarket groups. These improvements, together with a good performance in the smaller Belgian market, were partly offset by lower sales in the Netherlands. In Italy additional business was won with a number of new customers and this contributed to the overall sales growth. In Poland another strong performance was achieved during the second year of ownership of Intersilesia. A further expansion of the factory was completed during the year and significant new business was won with a number of western European retailers as they increased their presence in the Polish market. Sales offices were opened in Germany, Czech Republic and Hungary during the year, and these will provide opportunities for expansion into the important eastern European sector. It was reported in the Interim Review that a serious fire at the Estaimpuis factory in November 1999 had destroyed the raw material and packaging warehouse and the blow-moulding department. These areas of the factory were substantially rebuilt by the end of June and will be fully operational by December 2000. The full co-operation and support of McBride's insurers has assisted the recovery. Meanwhile effective management actions successfully minimised the effect on sales and customer service. Wrafton Laboratories McBride's purchase of 80% of Wrafton Laboratories in September 1999 was a key strategic development during the year. The market for OTC pharmaceuticals has been identified as an important growth opportunity. In the UK the total market is estimated to be worth £1.6 billion and is forecast to grow strongly as the combination of higher NHS prescription charges and increasing awareness of the effectiveness of OTC pharmaceuticals begins to be recognised by consumers. UK supermarkets are aiming to grow their share of traditional chemists products, and a key element of their product offering is the development of private label alternatives. Since its acquisition by McBride, Wrafton has accelerated its sales to retail customers and this trend is expected to continue as retailers increase the private label share of this large market. Joint venture In October 1999 McBride announced that Aerosol Products Ltd had been set up as a joint venture between Robert McBride and Nichol Beauty Products. The joint venture began trading in November 1999 and comprised the Hull factory of Robert McBride and the Thetford factory of Nichol Beauty Products. The closure of the Thetford site was completed in January 2000 with all production being moved to the Hull site. During the period of the run-down of Thetford and the transfer of equipment and stock to Hull, procedures and systems within the logistics function broke down, severely impacting customer service. This resulted in the company incurring an operating loss of which McBride's share was £2.4 million. However, the situation is now improving significantly and the company is moving into profit and regaining the confidence of its retail and contract customers. Mike Handley, Chief Executive and Deputy Chairman 23 October 2000 Consolidated profit and loss account Year ended 30 Year ended June 1999 30 June Before 1999 Year operating Operating Year ended exceptional exceptional ended 30 June items items 30 June 2000 1999 £m £m £m £m £m Turnover: Group and share of joint venture 511.1 496.8 - 496.8 Less: share of joint venture's turnover (14.3) - - - Group turnover 496.8 496.8 - 496.8 (including acquisitions of £18.5 million) Cost of sales (311.5) (307.8) (0.4) (308.2) Gross profit/(loss) 185.3 189.0 (0.4) 188.6 Distribution costs (23.3) (22.2) - (22.2) Administration costs: - Before goodwill (129.5) (131.9) (11.3) (143.2) amortisation - Goodwill amortisation (1.5) (0.4) - (0.4) Administrative costs including goodwill (131.0) (132.3) (11.3) (143.6) amortisation Group operating profit/(loss) (including acquisitions of 31.0 34.5 (11.7) 22.8 £1.1 million) Share of joint venture's operating loss before goodwill amortisation (2.2) - - - Goodwill amortisation on joint venture (0.2) - - - Share of joint venture's operating loss (2.4) - - - Profit on disposal of fixed assets 3.4 - - - Loss on transfer of business to joint venture (including goodwill (2.9) - - - previously written off to reserves of £1.4 million) Group interest receivable and similar income 0.2 0.1 - 0.1 Group interest payable and similar charges (6.6) (5.0) - (5.0) Share of joint venture's interest payable and similar charges (0.4) - - - Profit/(loss) on ordinary activities before taxation 22.3 29.6 (11.7) 17.9 Tax on profit/(loss) on ordinary activities (6.5) (7.5) 1.2 (6.3) Profit/(loss) on ordinary activities after taxation 15.8 22.1 (10.5) 11.6 Equity minority interest (0.4) (0.1) - (0.1) Profit/(loss) for the 15.4 22.0 (10.5) 11.5 period Dividends (8.2) (13.4) - (13.4) Retained profit/(loss) for 7.2 8.6 (10.5) (1.9) the period All operations above are continuing. Earnings per ordinary share (pence) Basic and diluted 8.7 6.5 Basic before operating exceptional items, share of joint venture and goodwill amortisation 10.8 12.7 Dividend per share (pence) 4.6 7.5 Balance sheets Group Group Company Company As at As at As at As at 30 June 30 June 30 June 30 June 2000 1999 2000 1999 £m £m £m £m Fixed assets Intangible assets 26.5 9.6 - - Tangible assets 153.8 147.7 0.2 0.2 Investments 7.5 - 173.5 164.0 Total fixed assets 187.8 157.3 173.7 164.2 Current assets Stocks 59.0 52.6 - - Debtors 104.8 93.1 73.7 63.7 Cash at bank and in hand 8.2 4.7 - - 172.0 150.4 73.7 63.7 Creditors: amounts falling due within one year (167.4) (150.2) (26.1) (34.8) Net current (liabilities)/assets 4.6 0.2 47.6 28.9 Total assets less current 192.4 157.5 221.3 193.1 liabilities Creditors: amounts falling due after more than one year (116.8) (90.2) (52.2) (18.0) Provisions for liabilities and charges (0.9) (16.3) - (15.0) Investment in joint venture Share of gross assets 10.5 - - - Share of gross liabilities (15.7) - - - Net investment in joint venture (5.2) - - - Net assets 69.5 51.0 169.1 160.1 Capital and reserves Called up share capital 17.8 17.8 17.8 17.8 Share premium account 139.3 139.3 139.3 139.3 Profit and loss account (88.8) (106.2) 12.0 3.0 Equity shareholders' funds 68.3 50.9 169.1 160.1 Equity minority interest 1.2 0.1 - - Net assets 69.5 51.0 169.1 160.1 These financial statements were approved the Board of Directors on 23 October 2000 and were signed on its behalf by: M Handley T J Monks Directors Consolidated cash flow statement Year Year Year Year ended 30 ended 30 ended 30 ended 30 June 2000 June 2000 June 1999 June 1999 £m £m £m £m Cash flow from operating 43.0 48.2 activities Returns on investments and servicing of finance (6.2) (5.1) Taxation (5.3) (6.8) Operating cash flow after taxation and finance costs 31.5 36.3 Capital expenditure Cash expenditure on fixed assets (24.5) (20.6) Insurance proceeds on loss of tangible fixed assets 2.3 - Disposal of fixed assets 0.3 1.4 (21.9) (19.2) Acquisitions Purchase of subsidiary (22.2) (8.1) undertakings Overdrafts acquired with subsidiaries (0.4) (0.6) Other payments - (2.0) Deferred consideration payments (1.9) (11.8) (24.5) (22.5) Equity dividends paid (13.5) (13.2) Cash flow before financing (28.4) (18.6) Financing 28.8 14.8 Increase/(decrease) in cash in the year 0.4 (3.8) Reconciliation of net cash flow to movement in net debt Year ended Year ended 30 June 30 June 2000 1999 £m £m Increase/(decrease) in cash in the year 0.4 (3.8) Cash outflow from movement in debt and lease financing (29.4) (16.5) Movement on finance leases 0.6 1.8 Change in net debt resulting from cash flows (28.4) (18.5) Loans and finance leases acquired with subsidiaries (2.6) (1.5) Translation differences 2.3 0.1 Movement in net debt in the year (28.7) (19.9) Net debt at the beginning of the year (86.3) (66.4) Net debt at the end of the year (115.0) (86.3) Consolidated statement of total recognised gains and losses Year ended Year ended 30 June 30 June 2000 1999 £m £m Profit for the financial year 15.4 11.5 Unrealised foreign currency differences (0.2) 0.5 Total recognised gains and losses relating to the financial year 15.2 12.0 Reconciliation of movements in shareholders' funds Year ended Year ended 30 June 30 June 2000 1999 £m £m Profit for the financial year 15.4 11.5 Equity dividends (8.2) (13.4) Retained profit/(loss) at the year end 7.2 (1.9) New share capital subscribed - 2.8 Unrealised foreign currency differences (0.2) 0.5 Goodwill written back/(off) to profit and loss account and reserves 10.4 (1.5) Opening shareholders' funds 50.9 51.0 Closing shareholders' funds 68.3 50.9 Notes to the financial statements Segmental Information Year ended Year 30 June ended 2000 £m 30 June 1999 £m Turnover by destination is analysed by geographical area as follows: United Kingdom 269.5 258.1 Continental Europe 223.0 232.9 Rest of World 4.3 5.8 Group turnover 496.8 496.8 Share of joint venture's turnover 14.3 - Turnover: Group and share of joint venture 511.1 496.8 Turnover by geographical origin is analysed as follows: United Kingdom 274.4 265.1 Continental Europe 222.4 231.7 Group turnover 496.8 496.8 Share of joint venture's turnover 14.3 - Turnover: Group and share of joint venture 511.1 496.8 Turnover by class of business is analysed as follows: Household products 406.6 406.1 Personal care products 71.7 90.7 Pharmaceuticals 18.5 - Group turnover 496.8 496.8 Share of joint venture's turnover 14.3 - Turnover: Group and share of joint venture 511.1 496.8 Operating profit by geographical origin is analysed as follows: United Kingdom 17.7 18.6 Continental Europe 13.3 4.2 Operating profit 31.0 22.8 Non operating items (2.3) - Net interest payable (6.4) (4.9) Profit on ordinary activities before tax 22.3 17.9 The UK business includes goodwill amortisation of £1.3 million and the Continental Europe business goodwill amortisation of £0.2 million. Year Year ended ended 30 June 30 June 2000 £m 1999 £m Operating profit by class of business is analysed as follows: Household products 28.5 27.2 Personal care products 1.4 (4.4) Pharmaceuticals 1.1 - Operating profit 31.0 22.8 Non operating items (2.3) - Net interest payable (6.4) (4.9) Profit on ordinary activities before tax 22.3 17.9 The household business includes goodwill amortisation of £0.9 million and the pharmaceutical business goodwill amortisation of £0.6 million. As at As at 30 June 30 June 2000 1999 £m £m Non operating items consist of the following: Profit on disposal of fixed assets 3.4 - Loss on transfer of business to joint venture (2.9) - Share of joint venture's operating loss (2.4) - Share of joint venture's interest payable and similar charges (0.4) - Total non operating items (2.3) - As at As at 30 June 30 June 2000 1999 £m £m Net assets by geographical origin are analysed as follows: United Kingdom 84.8 81.6 Continental Europe 81.7 88.5 166.5 170.1 Non operating liabilities (102.3) (119.1) Net assets 64.2 51.0 Non operating liabilities include cash less short and long-term borrowings, provisions for liabilities and charges and dividends. It is not possible to provide an analysis of the net assets by class of business as a number of the Group's operating sites manufacture both private label household and personal care products. Notes: 1.The financial information set out above for the year ended 30 June 2000 does not constitute statutory accounts as defined in section 240 of the Companies Act 1985, but is derived from those accounts. The statutory accounts for the year ended 30 June 1999 have been delivered to the Registrar of Companies and those for 2000 will be delivered following the Company's Annual General Meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under Section 237 (2) of (3) of the Companies Act 1985. 2.The Annual Report for 2000 will be issued to shareholders on 10 November 2000 and will be available from the Company Secretary at the Company's registered office, McBride House, Penn Road, Beaconsfield, Buckinghamshire HP9 2FY; the Annual General Meeting will be held on 7 December 2000. 3.The calculation of earnings per share is based on the profit on ordinary activities after taxation divided by the average number of shares in issue during the year of 177,639,197 (1999: 176,869,413). 4.If approved at the Annual General Meeting on 7 December 2000, the final dividend of 2.0p per share will be paid on 18 December 2000 to shareholders on the register at 17 November 2000.

Companies

Mcbride (MCB)
UK 100

Latest directors dealings